ICU Medical (ICUI) Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ICU Medical in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ICUI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ICUI, but not buy additional shares or sell existing shares.
View ICUI analyst ratings or view top-rated stocks.

1 brokers have issued 1 year target prices for ICU Medical's stock. Their ICUI share price forecasts range from $216.00 to $216.00. On average, they predict the company's stock price to reach $216.00 in the next twelve months. This suggests a possible upside of 86.1% from the stock's current price.
View analysts price targets for ICUI or view top-rated stocks among Wall Street analysts.

ICU Medical's stock was trading at $157.48 at the beginning of the year. Since then, ICUI stock has decreased by 26.3% and is now trading at $116.06.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our ICUI earnings forecast.

ICU Medical, Inc. (NASDAQ:ICUI) announced its quarterly earnings data on Monday, August, 7th. The medical instruments supplier reported $1.58 earnings per share for the quarter, topping the consensus estimate of $1.15 by $0.43. The medical instruments supplier earned $549.31 million during the quarter, compared to analysts' expectations of $562.90 million. ICU Medical had a positive trailing twelve-month return on equity of 6.93% and a negative net margin of 2.11%.

ETFs with the largest weight of ICU Medical (NASDAQ:ICUI) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), Fidelity Disruptive Medicine ETF (FMED) and Principal Healthcare Innovators ETF (BTEC) and

ICU Medical updated its FY23 earnings guidance on Tuesday, August, 8th. The company provided earnings per share guidance of $6.00-6.85 for the period, compared to the consensus estimate of $6.70.

81 employees have rated ICU Medical Chief Executive Officer Vivek Jain on Glassdoor.com. Vivek Jain has an approval rating of 73% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other ICU Medical investors own include Becton, Dickinson and Company (BDX), BlackRock (BLK), NVIDIA (NVDA), Alibaba Group (BABA), CA (CA), UnitedHealth Group (UNH), Boeing (BA), Micron Technology (MU), Lockheed Martin (LMT) and ServiceNow (NOW).

ICU Medical trades on the NASDAQ under the ticker symbol "ICUI."

ICU Medical's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.12%), JPMorgan Chase & Co. (3.00%), Victory Capital Management Inc. (2.66%), State Street Corp (2.52%), Segall Bryant & Hamill LLC (1.54%) and Allspring Global Investments Holdings LLC (1.34%). Insiders that own company stock include Christian B Voigtlander, Daniel Woolson, Elisha W Finney, George A Lopez, Robert S Swinney, Virginia Ruth Sanzone and Vivek Jain.
View institutional ownership trends.

Shares of ICUI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ICUI stock can currently be purchased for approximately $116.06.

ICU Medical (NASDAQ:ICUI) has a market capitalization of $2.80 billion and generates $2.28 billion in revenue each year. The medical instruments supplier earns $-74,290,000.00 in net income (profit) each year or ($2.02) on an earnings per share basis.

The company employs 14,500 workers across the globe.

ICU Medical's mailing address is 951 CALLE AMANECER, SAN CLEMENTE CA, 92763. The official website for the company is www.icumed.com. The medical instruments supplier can be reached via phone at (949) 366-2183, via email at ir@icumed.com, or via fax at 949-366-8368.